Savara Inc (SVRA)

07:09 AM

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI - PharmiWeb.com

07:09 AM

06:37 AM

How Savara Inc. (YB4P) stock compares with top peersDividend Hike & Growth Focused Entry Point Reports - ulpravda.ru

06:37 AM

06:20 AM

How Savara Inc. stock compares to growth peers2025 Institutional Moves & AI Optimized Trading Strategy Guides - ulpravda.ru

06:20 AM

04:05 AM

PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* - Yahoo Finance

04:05 AM

01:35 AM

Will Savara Inc. stock outperform tech sector in 2025July 2025 Technicals & Technical Buy Zone Confirmation - ulpravda.ru

01:35 AM

12:21 PM

How Savara Inc. stock benefits from global expansionJuly 2025 Movers & Fast Gaining Stock Strategy Reports - ulpravda.ru

12:21 PM

11:41 AM

Will Savara Inc. (YB4P) stock rise with strong economyBuy Signal & Fast Exit Strategy with Risk Control - ulpravda.ru

11:41 AM

11:01 AM

Will Savara Inc. stock reach all time highs in 20252025 Market Sentiment & Safe Investment Capital Preservation Plans - ulpravda.ru

11:01 AM

08:15 AM

Aug Volume: How Savara Inc stock compares to growth peersRisk Management & Growth Focused Investment Plans - moha.gov.vn

08:15 AM

Jan 06, 2026

Will Savara Inc. stock benefit from sector rotation2026 world cup usa national team group stage key players transition play expert forecast insights - ulpravda.ru

Jan 06, 2026

Dec 31, 2025

Oppenheimer Assumes Coverage of Savara (SVRA) With an Outperform Rating - MSN

Dec 31, 2025

Dec 31, 2025

FDA Clock Restarts: Savara Refiles MOLBREEVI for Rare Lung Disease - MyChesCo

Dec 31, 2025

Dec 30, 2025

Savara (NASDAQ:SVRA) Shares Down 5.1%Should You Sell? - MarketBeat

Dec 30, 2025

Dec 30, 2025

Savara Inc. (NASDAQ:SVRA) Short Interest Up 33.1% in December - MarketBeat

Dec 30, 2025

Dec 29, 2025

Death Cross: Is Savara Inc stock a defensive play in 2025Market Growth Summary & Safe Capital Growth Plans - moha.gov.vn

Dec 29, 2025

Dec 28, 2025

Savara Heads to JPMorgan Conference as Investors Watch Rare Lung Drug - MyChesCo

Dec 28, 2025

Dec 28, 2025

With 37% Ownership in Savara Inc. (NASDAQ:SVRA), Institutional Investors Have a Lot Riding on the Business - 富途牛牛

Dec 28, 2025

Dec 28, 2025

Swedbank AB Takes $1.96 Million Position in Savara Inc. $SVRA - MarketBeat

Dec 28, 2025

Dec 28, 2025

Gap Down: Is Savara Inc YB4P stock a buy for dividend portfolios2025 Trade Ideas & AI Based Buy and Sell Signals - moha.gov.vn

Dec 28, 2025

Dec 28, 2025

How Savara Inc. stock reacts to Fed rate cutsSector Performance Review & Your Free Entry to Smart Investing Starts Here - bollywoodhelpline.com

Dec 28, 2025

Dec 26, 2025

Savara price target raised to $10 from $8 at HC Wainwright - MSN

Dec 26, 2025

Dec 26, 2025

Savara Inc. ticks higher amid takeover speculation - MSN

Dec 26, 2025

Dec 25, 2025

Market Review: How MTEN stock performs in high volatility marketsMarket Trend Report & Accurate Intraday Trade Tips - moha.gov.vn

Dec 25, 2025

Dec 25, 2025

What is HC Wainwright's Forecast for Savara FY2027 Earnings? - MarketBeat

Dec 25, 2025

Dec 24, 2025

Savara (SVRA) Stock Price, Quote, News & History - Benzinga

Dec 24, 2025

Dec 24, 2025

FY2029 Earnings Estimate for Savara Issued By HC Wainwright - MarketBeat

Dec 24, 2025

Dec 24, 2025

SVRA SEC FilingsSavara Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Dec 24, 2025

Dec 23, 2025

Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission By Investing.com - Investing.com South Africa

Dec 23, 2025

Dec 23, 2025

Savara (SVRA) Receives Revised Buy Rating from HC Wainwright & C - GuruFocus

Dec 23, 2025

Dec 23, 2025

Savara stock price target raised to $10 from $8 at H.C. Wainwright By Investing.com - Investing.com Nigeria

Dec 23, 2025

Dec 23, 2025

Savara stock advances as Guggenheim reiterates Buy rating on BLA resubmission - Investing.com Nigeria

Dec 23, 2025

Dec 23, 2025

Savara stock price target raised to $10 from $8 at H.C. Wainwright - Investing.com Nigeria

Dec 23, 2025

Dec 23, 2025

How Investors May Respond To Savara (SVRA) Joining S&P Biotech Index After Key MOLBREEVI Patent Win - simplywall.st

Dec 23, 2025

Dec 22, 2025

Savara resubmits BLA for rare lung disease treatment with new manufacturer - Investing.com Nigeria

Dec 22, 2025

Dec 22, 2025

Savara (SVRA) Resubmits Molbreevi BLA to FDA for Autoimmune PAP Treatment - GuruFocus

Dec 22, 2025

Dec 22, 2025

Savara Resubmits Molbreevi Application to FDA for Rare Lung Disease - marketscreener.com

Dec 22, 2025

Dec 22, 2025

Savara Advances MOLBREEVI Toward Approval as Financing Boost Extends Cash Runway - MSN

Dec 22, 2025

Dec 22, 2025

Savara resubmits the Biologics License Application to the U.S. Food and Drug Administration for Molbreevi - marketscreener.com

Dec 22, 2025

Dec 22, 2025

Savara resubmits BLA for rare lung disease treatment with new manufacturer By Investing.com - Investing.com South Africa

Dec 22, 2025

Dec 22, 2025

Savara : Corporate Presentation - marketscreener.com

Dec 22, 2025

Dec 22, 2025

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - Yahoo Finance

Dec 22, 2025

Dec 21, 2025

Savara Inc.(NasdaqGS: SVRA) added to S&P Biotechnology Select Industry Index - marketscreener.com

Dec 21, 2025

Dec 21, 2025

Savara Locks In Long-Term Europe Protection for Rare Lung Drug MOLBREEVI - MyChesCo

Dec 21, 2025

Dec 21, 2025

Why Savara Inc. stock could rally in 2025Market Volume Summary & Daily Technical Forecast Reports - Улправда

Dec 21, 2025